298 related articles for article (PubMed ID: 16813519)
1. Expression of mouse osteoclast K-Cl Co-transporter-1 and its role during bone resorption.
Kajiya H; Okamoto F; Li JP; Nakao A; Okabe K
J Bone Miner Res; 2006 Jul; 21(7):984-92. PubMed ID: 16813519
[TBL] [Abstract][Full Text] [Related]
2. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
[TBL] [Abstract][Full Text] [Related]
3. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification.
Henriksen K; Sørensen MG; Nielsen RH; Gram J; Schaller S; Dziegiel MH; Everts V; Bollerslev J; Karsdal MA
J Bone Miner Res; 2006 Jan; 21(1):58-66. PubMed ID: 16355274
[TBL] [Abstract][Full Text] [Related]
4. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
Okamoto M; Murai J; Yoshikawa H; Tsumaki N
J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
[TBL] [Abstract][Full Text] [Related]
5. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
Nijenhuis T; van der Eerden BC; Hoenderop JG; Weinans H; van Leeuwen JP; Bindels RJ
J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro.
Morko J; Kiviranta R; Mulari MT; Ivaska KK; Väänänen HK; Vuorio E; Laitala-Leinonen T
Bone; 2009 Apr; 44(4):717-28. PubMed ID: 19118660
[TBL] [Abstract][Full Text] [Related]
7. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
8. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
9. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
10. Roles for KCC transporters in the maintenance of lens transparency.
Chee KS; Kistler J; Donaldson PJ
Invest Ophthalmol Vis Sci; 2006 Feb; 47(2):673-82. PubMed ID: 16431967
[TBL] [Abstract][Full Text] [Related]
11. Diphenylhydantoin inhibits osteoclast differentiation and function through suppression of NFATc1 signaling.
Koide M; Kinugawa S; Ninomiya T; Mizoguchi T; Yamashita T; Maeda K; Yasuda H; Kobayashi Y; Nakamura H; Takahashi N; Udagawa N
J Bone Miner Res; 2009 Aug; 24(8):1469-80. PubMed ID: 19292614
[TBL] [Abstract][Full Text] [Related]
12. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
13. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation.
Schaller S; Henriksen K; Sveigaard C; Heegaard AM; Hélix N; Stahlhut M; Ovejero MC; Johansen JV; Solberg H; Andersen TL; Hougaard D; Berryman M; Shiødt CB; Sørensen BH; Lichtenberg J; Christophersen P; Foged NT; Delaissé JM; Engsig MT; Karsdal MA
J Bone Miner Res; 2004 Jul; 19(7):1144-53. PubMed ID: 15176998
[TBL] [Abstract][Full Text] [Related]
14. An osteoclastic protein-tyrosine phosphatase is a potential positive regulator of the c-Src protein-tyrosine kinase activity: a mediator of osteoclast activity.
Lau KH; Wu LW; Sheng MH; Amoui M; Suhr SM; Baylink DJ
J Cell Biochem; 2006 Apr; 97(5):940-55. PubMed ID: 16267838
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase.
Kaji H; Sugimoto T; Kanatani M; Fukase M; Kumegawa M; Chihara K
J Bone Miner Res; 1996 Jan; 11(1):62-71. PubMed ID: 8770698
[TBL] [Abstract][Full Text] [Related]
16. Degradation of hydroxyapatite in vivo and in vitro requires osteoclastic sodium-bicarbonate co-transporter NBCn1.
Riihonen R; Nielsen S; Väänänen HK; Laitala-Leinonen T; Kwon TH
Matrix Biol; 2010 May; 29(4):287-94. PubMed ID: 20079835
[TBL] [Abstract][Full Text] [Related]
17. S 12911-2 inhibits osteoclastic bone resorption in vitro.
Takahashi N; Sasaki T; Tsouderos Y; Suda T
J Bone Miner Res; 2003 Jun; 18(6):1082-7. PubMed ID: 12817762
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor-alpha: alternative role as an inhibitor of osteoclast formation in vitro.
Balga R; Wetterwald A; Portenier J; Dolder S; Mueller C; Hofstetter W
Bone; 2006 Aug; 39(2):325-35. PubMed ID: 16580896
[TBL] [Abstract][Full Text] [Related]
19. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
Fuller K; Lindstrom E; Edlund M; Henderson I; Grabowska U; Szewczyk KA; Moss R; Samuelsson B; Chambers TJ
Bone; 2010 May; 46(5):1400-7. PubMed ID: 20097319
[TBL] [Abstract][Full Text] [Related]
20. Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro.
Lalande A; Roux S; Denne MA; Stanley ER; Schiavi P; Guez D; De Vernejoul MC
J Bone Miner Res; 2001 Feb; 16(2):361-70. PubMed ID: 11204436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
